| |
| |
|
| Insider
Information: |
Orbimed Genesis Gp Llc |
| Relationship: |
Director, 10% Owner |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
14 |
|
| Direct
Shares |
0 |
|
|
Indirect Shares
|
54,609,900 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$116,533,947 |
|
|
| Total
Shares |
54,609,900 |
|
|
| Total
Value |
$116,533,947 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Keros Therapeutics, Inc. |
KROS |
Director |
2020-04-13 |
0 |
2020-04-13 |
1,119,812 |
Premium* |
|
|
Scpharmaceuticals Inc. |
SCPH |
10% Owner |
2020-05-21 |
0 |
2022-11-25 |
5,559,528 |
Premium* |
|
|
Logicbio Therapeutics, Inc. |
LOGC |
Director, 10% Owner |
2020-10-01 |
0 |
2020-10-01 |
296,296 |
Premium* |
|
|
Galecto Inc. |
GLTO |
Director, 10% Owner |
2020-11-02 |
0 |
2020-11-02 |
1,031,811 |
Premium* |
|
|
Edgewise Therapeutics, Inc. |
EWTX |
Director, 10% Owner |
|
0 |
2024-01-23 |
14,756,096 |
Premium* |
|
|
Ikena Oncology, Inc. |
IKNA |
Director |
2021-03-30 |
0 |
2023-08-04 |
7,928,543 |
Premium* |
|
|
Alpine Immune Sciences Inc |
ALPN |
Director |
2021-09-17 |
0 |
2024-05-18 |
0 |
Premium* |
|
|
Theseus Pharmaceuticals, Inc. |
THRX |
Director, 10% Owner |
2021-10-12 |
0 |
2024-02-14 |
0 |
Premium* |
|
|
Janux Therapeutics, Inc. |
JANX |
Director |
2021-12-16 |
0 |
2021-12-29 |
231,098 |
Premium* |
|
|
Sierra Oncology Inc |
SRRA |
Director, 10% Owner |
2022-01-26 |
0 |
2022-01-26 |
226,704 |
Premium* |
|
|
Pmv Pharmaceuticals, Inc. |
PMVP |
10% Owner |
2022-05-26 |
0 |
2023-11-22 |
6,475,291 |
Premium* |
|
|
Terns Pharmaceuticals, Inc. |
TERN |
Director, 10% Owner |
2022-08-16 |
0 |
2022-12-23 |
7,619,135 |
Premium* |
|
|
Disc Medicine, Inc |
IRON |
Director |
2023-12-18 |
0 |
2023-12-18 |
1,702,237 |
Premium* |
|
|
Enliven Therapeutics Ord Shs |
ELVN |
Director, 10% Owner |
2023-02-23 |
0 |
2024-05-16 |
7,663,349 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
58 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-01-11 |
4 |
B |
$9.81 |
$89,319 |
I/I |
8,500 |
16,348,018 |
2.25 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-01-12 |
4 |
B |
$10.06 |
$190,104 |
I/I |
18,897 |
16,366,915 |
2.25 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-01-13 |
4 |
B |
$9.43 |
$163,328 |
I/I |
17,320 |
16,384,235 |
2.25 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-01-19 |
4 |
B |
$9.97 |
$114,864 |
I/I |
11,521 |
16,395,756 |
2.25 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-01-20 |
4 |
B |
$9.95 |
$348,250 |
I/I |
35,000 |
16,430,756 |
2.25 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-01-21 |
4 |
B |
$9.97 |
$1,115,603 |
I/I |
111,896 |
16,542,652 |
2.25 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-11-07 |
4 |
B |
$5.21 |
$1,000,320 |
I/I |
192,000 |
16,734,518 |
2.25 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2024-02-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(17,713,600) |
0 |
0 |
- |
|
58 Records found
|
|
Page 3 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
